InvestorWire NewsRoom

Articles

Articles Category: CBD
Wednesday Jan 25, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability to Meet Underserved Medical Needs

Bioavailability measures the amount of a substance that enters the bloodstream, with most oral routes providing lower amounts of the drug due to poor bioavailability Studies on nutrients show that not all the nutrients we ingest actually enter the bloodstream due to inhibiting factors in the digestive tract Lexaria’s patented DehydraTECH(TM) technology helps increase bioavailability for active pharmaceutical ingredients (“APIs”), which has been shown through…

Continue Reading

Tuesday Jan 17, 2023 - 12:00 pm

India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s

Believed to be the first natural low-doses of THC-based compound to enter human trials for Alzheimer’s IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease The clinical trial is expected to produce data to “help us to further understand the metabolism of IGC-AD1 for a diverse population,” says CEO In a historic first, India Globalization Capital (NYSE American: IGC) has begun Phase 2…

Continue Reading

Wednesday Jan 11, 2023 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Adds to its Existing Suite of Global Patents with First Granted Patent in Canada

Lexaria has announced patent #3,093,414, its first patent in Canada, its 28th granted patent worldwide, and the first patent from its sixth patent family This patent joins the ranks of previously issued patents in Australia, India, Japan, and the EU, even as similar patent applications for skin-based delivery of patented DehydraTECH formulations remain pending in many countries In Lexaria’s 2018 study, DehydraTECH-processed CBD demonstrated almost…

Continue Reading

Monday Jan 09, 2023 - 10:30 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM)-Processed CBD Can be Administered More Effectively at Lower Levels than Other CBD, Boosting Hope for Hypertension Patients

Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure The company also reported that…

Continue Reading

Friday Jan 06, 2023 - 11:15 am

Flora Growth Corp. (NASDAQ: FLGC) Acquisition of Franchise Global Health Completed, Rapid Jump in Potential for European Cannabis Sales

International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies…

Continue Reading

Wednesday Jan 04, 2023 - 11:15 am

Dosing Begins in Lexaria Bioscience Corp. (NASDAQ: LEXX) Human Clinical Study, Evaluating DehydraTECH(TM)-Nicotine Against Leading Nicotine Oral Pouch Brands

The 36-person human pharmacokinetic randomized, double-blind, cross-over study NIC-H22-1 will compare its patented DehydraTECH(TM)-nicotine to leading nicotine pouches On! and Zyn The white pouch oral delivery of nicotine is thought to avoid harmful lung outcomes that smokers and vapers experience The global nicotine pouch market was valued at $2.33 billion in 2020 and is expected to reach $21.84 billion by 2027, driven by an increase…

Continue Reading

Wednesday Dec 28, 2022 - 9:00 am

M&A Activity Keeps Flora Growth Corp. (NASDAQ: FLGC) Revenues Strong Amid Expected Rebound in Cannabis Industry

Cannabis cultivator and international brand developer Flora Growth has continued to build its revenues through accretive acquisitions during the past year and expects to see revenues continue to rise amid further M&A activity Flora expects to lock in its latest acquisition by the end of the month after shareholders meet to discuss the proposed deal with multi-national operator Franchise Global Health (“FGH”), which would grant…

Continue Reading

Tuesday Dec 27, 2022 - 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Uses Patented DehydraTECH(TM) Technology to Increase Bioavailability in Pharmaceuticals

Studies have indicated that around 40% of the available drugs on the market offer poor bioavailability Lexaria’s patented DehydraTECH(TM) technology increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery The global pharmaceutical drug delivery market was valued at $1.66 billion in 2021 and is expected to grow at a CAGR of 5.9%, resulting in a value…

Continue Reading

Thursday Dec 22, 2022 - 9:00 am

Luis Merchan, Helping Flora Growth Corp. (NASDAQ: FLGC) Become Global Leader in the CBD Space

Luis Merchan was appointed President of Consumer Goods at Flora in July 2020 before being appointed as the company’s CEO five months later, and chairman of its Board of Directors in May 2022 Merchan would lend his years of experience at Macy’s, where he led various sales and marketing initiatives, including the B2B corporate team responsible for bringing in $160 million in annual revenue  Under…

Continue Reading

Thursday Dec 15, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing the Seizure Treatment Market with Successful EPIL-A21-1 Animal Study

Epilepsy affects one in every 26 people globally, with as many as one million ED visits, 280 hospital admissions, average hospital stays of 3.6 days, and an aggregate hospital cost of approximately $2.5 billion annually With its severity, prevalence, and overall cost implications, Lexaria is looking to offer an alternative option with its patented DehydraTECH(TM)-CBD Its recent animal seizure study, EPIL-A21-1, showed DehydraTECH-CBD to be…

Continue Reading

Tuesday Dec 13, 2022 - 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) 2022 Calendar Year in Review

Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements Lexaria started and completed its fourth and most comprehensive hypertension study yet,…

Continue Reading

Wednesday Dec 07, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Findings of Animal Anti-Seizure Study Program Suggesting that DehydraTECH(TM)-CBD Is More Effective at Lower Doses and Works More Rapidly than FDA-Approved Epidiolex

Lexaria recently announced the findings of the first two studies from its EPIL-A21-1 animal research program The program is designed to assess the effectiveness of patented DehydraTECH(TM)-CBD in reducing or eliminating seizure activity compared to Epidiolex, a CBD-based anti-seizure drug The first study evidenced that DehydraTECH-CBD is more efficacious at lower doses than Epidiolex The second study demonstrated DehydraTECH-CBD’s enhanced effectiveness; specifically, the formulation acted…

Continue Reading

Friday Dec 02, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves Forward With Exploration of Patented DehydraTECH(TM)-Processed CBD for Dementia

Approximately 55 million people worldwide have dementia, which is expected to grow to 78 million by 2030 The dementia treatment market was valued at $13.78 billion in 2021. The market is expected to grow at a CAGR of 8.32%, resulting in a value of $26.13 billion by 2029 Clinical studies have established a connection between hypertension and dementia With DehydraTECH(TM)-CBD already evidencing that it can…

Continue Reading

Tuesday Nov 29, 2022 - 1:30 pm

Prime Harvest Inc. Positioned to Lead California’s Cannabis Market with Direct-to-Consumer Expansion

Prime Harvest is the parent company of Jaxx Cannabis, its D2C operations actively expanding throughout California Prime Harvest’s brand partners strongly positioned across multiple segments of the cannabis value chain Brand partners include Mary's Medicinals, STIIIZY, Lime Cannabis, and Tonik Revenue diversification is critical to sustainable growth in the cannabis industry, and it’s central to the strategy of Prime Harvest, a technology-focused, full-service cannabis corporation.…

Continue Reading

Tuesday Nov 29, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Investigation of DehydraTECH-CBD’s Potential Therapeutic Value for Diabetes and Defmentia with New Studies

Lexaria’s Patented DehydraTECH technology improves the bioavailability of pharmaceuticals and therapeutics for a number of developing applications Lexaria is set to complete its DEM-A22-1 and DIAB-A22-1 studies on dementia and diabetes, respectively, in January 2023, with analysis and reporting set to follow soon after These studies will build on the just-concluded hypertension clinical study whose results were “truly exceptional,” demonstrating a statistically significant lowering of…

Continue Reading

Wednesday Nov 23, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Launches Animal Study to Evaluate Potential Therapeutic Effect of DehydraTECH-CBD on Dementia

Lexaria Bioscience has launched DEM-A22-1, its first-ever study to investigate whether its patented DehydraTECH(TM)-processed CBD may have therapeutic use against dementiaThe animal study will involve a total of 32 Long Evans rats and will involve a memory assessment test that will be utilized to investigate whether CBD enables cognitive performance enhancementsPrevious independent studies have shown that CBD prevents the development of a social recognition deficit,…

Continue Reading

Monday Nov 21, 2022 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetesThe company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetesLexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and…

Continue Reading

Thursday Nov 17, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Approved to Proceed with Human Study Evaluating Effectiveness of Patented DehydraTECH(TM) Technology in Boosting Oral-Tissue Absorption of Nicotine

Lexaria Bioscience recently received Independent Review Board approval for its upcoming human clinical nicotine study, NIC-H22-1, and expects to begin dosing soonThe company hopes to evidence that processing purified nicotine with its patented DehydraTECH(TM) drug delivery technology leads to better oral-tissue absorption and reduced negative experiences compared to leading brands currently available on the market, On! and ZynLast year, Lexaria conducted an animal study evaluating…

Continue Reading

Friday Nov 11, 2022 - 9:00 am

Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation

Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placeboAccording to a Zacks SCR report, the findings support their $15 share valuation of the companyZacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral productsThe hypertension drug market is expected to grow to over $34 billion through 2030,…

Continue Reading

Wednesday Nov 09, 2022 - 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Defines Path to Profitability and Portfolio Expansion with Proposed Franchise Global Health Inc. Acquisition

Flora Growth signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of agreementThe deal is expected to close in December following the presentation of the agreement to shareholders; the acquisition will open Flora to the German and EU medical markets, increasing the company’s international revenue and providing essential distribution to German pharmacies and…

Continue Reading

Tuesday Nov 08, 2022 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Aiming to Address Unmet Patient Needs of Hypertensive Patients

Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patientsWith the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation. 47% of adults live with hypertension but only 24% of them have it under controlWith its DehydraTECH-CBD, Lexaria hopes to not…

Continue Reading

Monday Nov 07, 2022 - 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Agreement to Acquire Multi-national Cannabis Operator Positions Company for New Strategic Growth in Europe

Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern ColombiaFlora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprintFGH is focused on the German market, where its subsidiary was the first company to sell…

Continue Reading

Friday Nov 04, 2022 - 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Zero Adverse Effects from Successful HYPER-H21-4 Study of DehydraTECH(TM)-CBD for High Blood Pressure

The CDC reported more than 670,000 annual deaths in the United States with high blood pressure as a primary or contributing causeLexaria's patented DehydraTECH(TM) technology has been shown, through HYPER-H21-4 study, to decrease high blood pressure in subjects through DehydraTECH-CBD-enabled dosingThe global antihypertension drug market was valued at over $22.5 billion in revenue in 2018 and is expected to grow at a CAGR of 3.1%,…

Continue Reading

Thursday Nov 03, 2022 - 10:30 am

Tampa Alternative Products Expo Brings Together The Local Community For Three Days of Festivity And Business Networking

After various successful shows across North and South America, Alternative Products Expo is coming to Tampa, Florida, this November 10-10, at Tampa's Convention Center. The event has something for everyone. It features over 250 industry vendors, 20+ speakers from across the industry, and many contests and giveaways. Starting some years ago with a series of successful Vape events, the Alt Pro Expo team ventured into…

Continue Reading

Thursday Nov 03, 2022 - 9:00 am

Cannabis Regulation in the Spotlight During Midterm Elections at the Heels of Presidential Pardon; Flora Growth Corp. (NASDAQ: FLGC) Leveraging Colombian Stance to Manufacture Products at Lower Costs

President Biden issued a pardon for federally incarcerated inmates with minor marijuana possession charges, urging governors to do the same at the state levelThe President also requested a reclassification of cannabis, as it is currently listed above other drugs which are key factors in the overdose epidemicFlora Growth, through its Colombian cultivation, is producing a higher quality product at lower-than-average cost margins due to the…

Continue Reading

Wednesday Nov 02, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Maintains Late 2022/Early 2023 for Full IND Application for DehydraTECH-CBD

Lexaria, through its patented DehydraTECH(TM) technology, is improving the bioavailability of pharmaceuticals and therapeutics (in part) by bypassing first-pass-liver processing, thereby achieving an improved speed of onset, and brain absorption of APIsHypertension currently affects nearly 50% of all American adults, with the American Heart Association describing it as a “silent killer”, and is now being studied for its effects during pregnancyThe company has received positive…

Continue Reading

Tuesday Nov 01, 2022 - 12:00 pm

Tampa Alternative Products Expo To Offer A Festive Vibe Amongst Business Networking

Exhibitors, speakers, businesses, CBD and alternative products vendors, and researchers, are all invited to attend the Tampa Alternative Products Expo 2022 at the Tampa Convention Center. With over 10,000 attendees, 300+ vendors, and 20+ speakers per event, the Expo will exude a festival-like vibe for Tampa's CBD, cannabis, and vape communities. The event is organized by ZJ Events, with a reputation for managing the nation's…

Continue Reading

Tuesday Nov 01, 2022 - 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Focusing on Execution and Brand Integration Following Successful Period of Strategic Investment

Flora Growth recently participated in an earnings call in which the management team discussed the company’s financials as well as its growth strategy and outlook for the remainder of fiscal 2022 as well as 2023The company noted it had exited a period of investment and is now focusing on executionThe period of investment saw the company acquire synergistic brands that, collectively, create a direct-to-consumer house…

Continue Reading

Monday Oct 31, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Moves to Address Adverse Effects of Hypertension with DehydraTECH(TM) – CBD

Lexaria is a drug delivery technology company developing DehydraTECH-CBD as a prospective registered treatment for hypertension and potentially other disease states beyond hypertensionThe company has undertaken multiple de-risking hypertension studies that have not only evidenced that DehydraTECH-CBD is safe and well tolerated, but have also shown that it reduces blood pressure and arterial stiffnessHypertension is a leading contributor to deaths in the United States, damaging…

Continue Reading

Wednesday Oct 26, 2022 - 9:00 am

Advanced Container Technologies Inc. (ACTX) Offers Growing Solution in Industry Seeing Key Government Support

California governor signs 10 cannabis-related bills into lawBills intended to “strengthen California’s cannabis laws, expand the legal cannabis market and redress the harms of cannabis prohibition”ACTX’s Grow Pods offer unmatched control, are capturing a great deal of attention in the cannabis and hemp space As California Gavin Newsom signed 10 cannabis-related legislative bills into law — all in one day (https://ibn.fm/ge2Kv) — companies operating in the…

Continue Reading

Tuesday Oct 25, 2022 - 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Potential Hypertension Medication Poised to Reduce Risk of Blood-Pressure-Induced Dementia, Cognitive Decline

Lexaria Bioscience is a global innovator in drug delivery platforms that has developed the patented DehydraTECH(TM) technology for improved delivery of bioactive compoundsThe company is currently evaluating DehydraTECH-processed CBD as a potential treatment for high blood pressureLong-term studies have shown that high blood pressure can increase the risk of developing dementia in later lifeExperts, however, believe that hypertension medication could slow the pace of the…

Continue Reading

Monday Oct 24, 2022 - 9:00 am

Advanced Container Technologies Inc. (ACTX) Leaders Talk Game-Changing Microfarm Growing Option on Episode of Leading Podcast

ACTX CEO Doug Heldoorn, Grow Pod inventor Shannon Illingworth discuss the innovative microfarm option on recent Gamechangers LIVE podcastDiscussion focuses on history of company, significant health and safety benefits of Grow PodsCompany is dedicated to developing, manufacturing and selling advanced cultivation equipment and packaging systems Advanced Container Technologies (OTC: ACTX) chair and CEO Doug Heldoorn was a featured guest on a recent episode of the…

Continue Reading

Wednesday Oct 19, 2022 - 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Building Portfolio of Brands that Resonates with End Consumers as It Targets Margins and Profitability

Flora Growth is a global cannabis company building a connected, design-led collective of plant-based wellness and lifestyle brandsThe company’s portfolio of brands is designed to deliver the most compelling customer experiences in the worldThrough its M&A strategy, Flora Growth has brought on board brands like JustCBD, Vessel Brands Inc., Masaya, No Cap Hemp Co., and MambeFlora hopes to establish meaningful connections with consumers through these…

Continue Reading

Monday Oct 17, 2022 - 9:45 am

Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Drug Development Program Seeking to Provide Safe, Well-Tolerated, Effective Antihypertensive Medication Amid Continued Reports of Suboptimal Adherence to Existing Treatments

Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffnessLexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medicationReasons…

Continue Reading

Monday Oct 17, 2022 - 9:00 am

Changing Legal Landscape for Cannabis in Colombia and the U.S. Portends a New Era of Productivity for Flora Growth Corp. (NASDAQ: FLGC)

Colombia and the United States have both recently exhibited new openness to the possibility of decriminalizing adult recreational cannabis use through legislative changeCannabis supplier Flora Growth cultivates its product at a key Colombian farm and provides it to international markets, and may see additional opportunities arise as cannabis policies advance in the two countriesFlora Growth recently announced completion of its first shipments of high-CBD dried…

Continue Reading

Thursday Oct 13, 2022 - 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Using Patented DehydraTECH(TM) Technology to Fight America’s Silent Killer – Hypertension

Three out of four adults living with hypertension do not have the condition under control, putting them at risk for other serious complicationsLexaria’s proposed therapy for hypertension is the highly efficient DehydraTECH-CBD, which has presented with no serious adverse side effects in test participantsDominated by the North American market, the global antihypertension drug market accounted for $22,557 million in 2018 and is expected to reach…

Continue Reading

Tuesday Oct 11, 2022 - 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Offering Solutions to Growing Hypertension Problem Worldwide

Hypertension affects nearly half of all adults in the United States – 47% or 116 million people, some of which are medication-resistantA recent study from the University of Toledo College of Medicine and Life Sciences concluded gut bacteria might be the cause of medication-resistant hypertension – as demonstrated in rats used to conduct the studyLexaria’s patented DehydraTECH(TM) technology offers a viable solution for hypertension drug…

Continue Reading

Monday Oct 10, 2022 - 11:15 am

Rosy Outlook for Global Cannabis Market Boosts Hopes for Flora Growth Corp. (NASDAQ: FLGC) as Supply Chain Expands

Cannabis grower and product maker Flora Growth is developing its own approach to riding troubling economic forces, boasting a 604 percent YOY increase in the H1 reporting period this yearMarket analysts predict the global cannabis market’s value will rise during the next five years at a CAGR of 24.3 percent to arrive at annual valuation of $82.3 billionFlora Growth is levying the potential of recent…

Continue Reading

Friday Oct 07, 2022 - 11:15 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification and High Prescription Abandonment Rates, with DehydraTECH-CBD

Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertensionA 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last ten yearsThis decline has been attributed to, among other possible reasons, the side effects of antihypertensive drugsAt the same time, only 24% of adults with hypertension have the condition under control,…

Continue Reading

Monday Oct 03, 2022 - 10:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Focusing on Multiple Mainstream Applications of Its Disruptive Patented DehydraTECH(TM) Technology

Lexaria is the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technologyDehydraTECH is designed to enhance the performance of fat-soluble active pharmaceutical ingredients (“APIs”), molecules, and drugs by increasing their bioavailabilityThrough animal and human studies, Lexaria has shown that DehydraTECH increases the bioavailability of antiviral drugs, CBD, oral nicotine and moreThe company is focusing on multiple mainstream applications of its technology that rerrcould address…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).